Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445755 | 0.86 | CYP1A2 (0.39) | CYP1A2AGBL2AKR1B1HSD17B10GABRA5 | |
| SCHEMBL501718 | 0.86 | AKR1B1 (0.38) | CYP1A2AGBL2AKR1B1KDM4ELMNA | |
| SCHEMBL15948192 | 0.82 | AKR1B1 (0.42) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL12445760 | 0.81 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL503968 | 0.79 | AKR1B1 (0.41) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL12445758 | 0.77 | CSNK2A2 (0.43) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL501844 | 0.77 | AKR1B1 (0.42) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL15948146 | 0.77 | AKR1B1 (0.39) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL15948206 | 0.74 | AKR1B1 (0.41) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E | |
| SCHEMBL12445753 | 0.73 | AGBL2 (0.39) | CYP1A2AGBL2AKR1B1HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | RAF1, BRAF, ARAF | CYP1A2 3240/4885AGBL2 2709/4885AKR1B1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.